Eko Health is a technology company.
Eko Health has raised $137.0M across 6 funding rounds.
Eko Health has raised $137.0M in total across 6 funding rounds.
Eko Health has raised $137.0M in total across 6 funding rounds.
Eko Health's investors include Vasudev Bailey, Artis Ventures (AV), Baird Capital, Echo Health Ventures, Endeavor Venture Funds, Highland Capital Partners, Hoxton Ventures, Oak HC/FT, Optum Ventures, Pieter Kemps, Presight Capital, Questa Capital.
Eko Health is a pioneering AI-powered digital health company that builds advanced digital stethoscopes, ECG devices, software platforms, and AI analysis tools to enable earlier detection and monitoring of heart and lung diseases.[1][5][6] It serves over 600,000 healthcare providers worldwide, including clinicians in hospitals, clinics, virtual care settings, and health systems operating 800+ US hospitals, solving the problem of inaccurate or missed diagnoses in noisy environments or remote exams by delivering high-fidelity audio, real-time ECG visualization, and FDA-cleared AI flagging murmurs, atrial fibrillation (AFib), low ejection fraction, and more in as little as 15 seconds.[1][4][6] With over 650,000 devices sold globally—the largest connected digital stethoscope network—Eko drives growth through telehealth integrations, life sciences partnerships for data generation, and expansions like its UK launch, enhancing virtual cardiac/pulmonary exams and scaling detection across physical and remote care.[1][2][4]
Eko Health, headquartered in Emeryville, California, emerged as a commercial-stage cardiac health technology company focused on reinventing the stethoscope into an AI-enabled early disease detection platform, akin to how Ring transformed doorbells into security systems.[1][7] Co-founder and CEO Connor Landgraf leads the team, backed by investors like Questa Capital, with key executives including Co-founder and Chief Business Officer Jason Bellet, who has highlighted Eko Telehealth's role in virtual care.[1][7] The idea stemmed from proprietary cardiac detection algorithms powering connected devices, gaining early traction through FDA clearances (9 total for devices and AI), partnerships like Mayo Clinic (50+ publications), and massive device adoption, evolving from core auscultation tools to a full ecosystem including telehealth streaming and bioPharma data solutions.[6][7]
Eko Health rides the wave of AI-driven telehealth and remote patient monitoring, capitalizing on post-pandemic demand for virtual care that matches in-person diagnostic quality amid clinician shortages and rising cardiopulmonary disease burdens (e.g., structural heart disease, pulmonary hypertension).[1][2] Timing is ideal as digital health matures—FDA clearances and 600,000+ users reflect market forces like EHR integrations, bioPharma needs for real-world data, and underdiagnosed conditions driving early intervention.[2][6] Eko influences the ecosystem by creating the world's largest connected stethoscope network, enabling scaled AI training, partnerships (e.g., Mayo, Imperial), and hybrid care models that reduce in-person visits while boosting accuracy, positioning it as a foundational tool in cardiology evolution.[1][4][7]
Eko Health is poised to dominate AI cardiopulmonary detection with expansions into new algorithms (pulmonary hypertension, respiratory disease), deeper bioPharma collaborations for digital biomarkers, and global scaling beyond UK/US.[2][4] Trends like hospital-at-home proliferation, AI regulatory tailwinds, and demand for remote physiological data will accelerate growth, potentially evolving Eko into a full-stack virtual exam platform influencing how 800M+ annual cardiac exams worldwide incorporate AI.[1][2] As the largest device network fuels richer datasets, Eko could redefine early disease detection, delivering the high-fidelity auscultation that powers next-gen care from clinic to anywhere.[1][5]
Eko Health has raised $137.0M across 6 funding rounds. Most recently, it raised $41.0M Series D in June 2024.